It was found that Tepmeko, a MET mutated anti-cancer drug that failed to set reimbursement standards, recently voluntarily withdrew its application for reimbursement. Tepmeko has not been recognized as valid as a result of discussing the reimbursement standard in HIRA. According to the industry on the 10th, Merck announced its intention to voluntarily withdraw Tepmeko's application for drug reimbursement decision to HIRA. Tepmeko is a treatment for locally advanced or metastatic non-small cell lung cancer with confirmed MET exon 14 deletion. In Korea, in November 2021, it was approved simultaneously with Tabrecta, a drug in the same family, and has been undergoing a full-scale reimbursement review since last year.